Yazar "Seval, Guldane Cengiz" seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Acute Myeloid Leukemia in Elderly, Unfit Patients: Analysis of Turkish AML Prospective Registry Database, on Behalf of Acute Leukemia Working Group of Turkish Society of Hematology(Amer Soc Hematology, 2023) Urlu, Selin Merih; Seval, Guldane Cengiz; Yucel, Elcin Erdogan; Mehtap, Ozgur; Yenihayat, Emel Merve; Polat, Merve Gokcen; Malkan, Umit Yavuz[Abstract Not Available]Öğe Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies(Galenos Yayincilik, 2022) Bozdag, Sinem Civriz; Seval, Guldane Cengiz; Hindilerden, Ipek Yonal; Hindilerden, Fehmi; Andic, Neslihan; Baydar, Mustafa; Kaynar, Lale AydinObjective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such as in patients with hematological malignancies, is a point of interest. We aimed to analyze the symptoms, complications, intensive care unit admissions, and mortality rates of patients with hematological malignancies infected with SARS-CoV-2 in Turkey. Materials and Methods: In this multicenter study, we included 340 adult and pediatric patients diagnosed with SARS-CoV-2 from March to November 2020. Diagnosis and status of primary disease, treatment schedules for hematological malignancies, time from last treatment, life expectancy related to the hematological disease, and comorbidities were recorded, together with data regarding symptoms, treatment, and outcome of SARS-CoV-2 infection. Results: Forty four patients were asymptomatic at diagnosis of SARSCoV-2 infection. Among symptomatic patients, fever, cough, and dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixtynine (20%) patients had mild SARS-CoV-2 disease, whereas moderate, severe, and critical disease was reported in 101 (29%), 71 (20%), and 55 (16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2 infection was 26.5% in the entire cohort; this comprised 4.4% of those patients with mild disease, 12.4% of those with moderate disease, and 83% of those with severe or critical disease. Active hematological disease, lower life expectancy related to primary hematological disease, neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line therapy used for coronavirus disease-2019 treatment were found to be related to higher mortality rates. Treatments with hydroxychloroquine alone or in combination with azithromycin were associated with a higher rate of mortality in comparison to favipiravir use. Conclusion: Patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of severe disease and mortality.Öğe Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable ?Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey(Cig Media Group, Lp, 2019) Beksac, Meral; Seval, Guldane Cengiz; Paydas, Semra; Tuglular, Tulin Firatli; Arslan, Onder; Goker, Hakan; Kaynar, Leylagul[Abstract Not Available]Öğe Idarubicin Versus Daunorubicin Versus Mitoxantrone for Induction Chemotherapy in Acute Myeloid Leukemia: Patient Registration Study of Turkish Society of HematologyAcute Myeloid Leukemia Working Group(Amer Soc Hematology, 2023) Pinar, Ibrahim Ethem; Celik, Serhat; Polat, Merve Gokcen; Karatas, Aylin Fatma; Dogan, Ali; Iltar, Utku; Seval, Guldane Cengiz[Abstract Not Available]Öğe Prospective Real-World Outcomes of Acute Myeloid Leukemia(Amer Soc Hematology, 2023) Karakus, Volkan; Iltar, Utku; Yenihayat, Emel Merve; Polat, Merve Gokcan; Celik, Serhat; Malkan, Umit Yavuz; Seval, Guldane Cengiz[Abstract Not Available]
